Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood cancer drug pirtobrutinib tested for Long-Term safety in ongoing study

NCT ID NCT06876662

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma (NHL) who were already in a previous trial. About 279 participants will continue their treatment or follow-up visits. The main goal is to track serious side effects and overall survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 279 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Dec 2032

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Are currently enrolled and active in the originator study, LOXO-BTK-18001. A participant is considered active in the study if they are: * receiving study intervention * in the short-term follow-up period, or * in the long-term follow-up period Exclusion Criteria: * Were a participant in the Phase 1b cohort of Study LOXO-BTK-18001

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic lymphocytic leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic lymphocytic leukemia Non-Hodgkin lymphoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    25 sites in 7 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU de Nantes - Hotel Dieu

    RECRUITING

    Nantes, 44093, France

  • Cayuga Cancer Center

    ACTIVE_NOT_RECRUITING

    Ithaca, New York, 14850, United States

  • Churchill Hospital

    RECRUITING

    Oxford, OX3 7LE, United Kingdom

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02115, United States

  • Derriford Hospital

    RECRUITING

    Plymouth, PL6 8DH, United Kingdom

  • Duke University Medical Center

    RECRUITING

    Durham, North Carolina, 27710-4000, United States

  • Flinders Medical Centre

    RECRUITING

    Adelaide, 5042, Australia

  • Florida Cancer Specialists

    RECRUITING

    Sarasota, Florida, 34232-6422, United States

  • Hokkaido University Hospital

    ACTIVE_NOT_RECRUITING

    Sapporo, 060-8648, Japan

  • IRCCS-AOU di Bologna-Policlinico S.Orsola-Malpighi

    COMPLETED

    Bologna, 40138, Italy

  • Instytut Hermatologii I Transfuzjologii

    RECRUITING

    Warsaw, 02-776, Poland

  • Linear Clinical Research

    ACTIVE_NOT_RECRUITING

    Victoria, 3000, Australia

  • Mayo Clinic- Minnesota

    RECRUITING

    Rochester, Minnesota, 55905, United States

  • Medical College of Wisconsin

    RECRUITING

    Milwaukee, Wisconsin, 53226-3548, United States

  • Memorial Sloan-Kettering Cancer Center (MSKCC) - New York

    RECRUITING

    New York, New York, 10065-6007, United States

  • Memorial Sloan-Kettering Cancer Center (MSKCC) - New York

    ACTIVE_NOT_RECRUITING

    New York, New York, 10065-6007, United States

  • Nagoya Medical Center

    ACTIVE_NOT_RECRUITING

    Aichi-Ken, 4600001, Japan

  • National Cancer Center Hospital

    COMPLETED

    Cho-ku, 104-0045, Japan

  • National Hospital Organization Kyushu Cancer Center

    ACTIVE_NOT_RECRUITING

    Fukuoka, 811-1395, Japan

  • Northwell Health

    RECRUITING

    Lake Success, New York, 11042-1118, United States

  • Northwestern University

    RECRUITING

    Chicago, Illinois, 60611-3013, United States

  • Ohio State University Comprehensive Cancer Center

    RECRUITING

    Columbus, Ohio, 43210-1063, United States

  • Ospedale San Raffaele

    RECRUITING

    Milan, 20132, Italy

  • Peter MacCallum Cancer Centre

    COMPLETED

    Melbourne, 3000, Australia

  • Pratia MCM Krakow

    RECRUITING

    Krakow, 30727, Poland

  • Seoul National University Hospital

    RECRUITING

    Seoul, 03080, South Korea

  • St James's University Hospital

    RECRUITING

    Leeds, LS9 7TF, United Kingdom

  • Swedish Cancer Institute

    RECRUITING

    Seattle, Washington, 98104-3588, United States

  • Sylvester Comprehensive Cancer Center

    RECRUITING

    Miami, Florida, 33136-1002, United States

  • Tennessee Oncology

    RECRUITING

    Nashville, Tennessee, 37203-2659, United States

  • The Emory Clinic

    RECRUITING

    Atlanta, Georgia, 30322-1013, United States

  • Tohoku University Hospital

    ACTIVE_NOT_RECRUITING

    Miyagi-Ken, 9808574, Japan

  • Tokai University Hospital- Isehara Campus

    ACTIVE_NOT_RECRUITING

    Isehara, 259-1193, Japan

  • University Of Nebraska Medical Center

    RECRUITING

    Omaha, Nebraska, 69198, United States

  • University of Pennsylvania Hospital

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • University of Texas MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030-4000, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.